Home Ingredients Eurycomanone (Tongkat Ali Quassinoid)
TestosteroneMen's HealthLibido SupportAthletic PerformanceStress & Anxiety

Eurycomanone (Tongkat Ali Quassinoid)

Eurycoma longifolia Jack — bioactive quassinoid
Evidence Level
Moderate
3 Clinical Trials
7 Documented Benefits
3/5 Evidence Score

Specific quassinoid alkaloid bioactive from Eurycoma longifolia (Tongkat Ali) root — distinct from full Tongkat Ali extract. Standardized branded extracts include Physta® (Biotropics Malaysia, 0.8-1.5% eurycomanone) and LJ100®. Leisegang 2022 (PMID 36013514, Medicina 58(8):1047) is the pivotal systematic review and meta-analysis (PRISMA, 9 studies in review, 5 RCTs in meta-analysis) — significant increase in total testosterone (SMD 1.352, 95% CI 0.565-2.138, p=0.001), confirmed in hypogonadism subgroup. Henkel 2021 (PMID 33541567) — 6-month 4-arm ADAM RCT (Androgen Deficiency of Aging Males): E. longifolia + concurrent training improved erectile function and testosterone in ~50% of participants. Tambi 2012 — 76 hypogonadism + LOH patients on Physta®. Most rigorous meta-analytic evidence base for any testosterone-supporting herbal supplement to date.

Studied Dose STANDARDIZED EXTRACTS: Physta® 200-400 mg/day (Tambi 2012 hypogonadism). LJ100®: 100-200 mg/day. PURIFIED EURYCOMANONE: 50-200 mg/day. Standard total range: 200-400 mg/day. Avoid in pregnancy and hormone-sensitive cancers. Standardized branded extracts preferable due to historical heavy metal contamination concerns with non-standardized Malaysian products.
Active Compound Eurycomanone (primary bioactive quassinoid). Additional bioactives: 9-hydroxycanthin-6-one (alkaloid), other quassinoids (β-anhydroxonoeurycomalactone, eurycolactone, etc.). Branded extracts standardize to specific eurycomanone content (Physta® 0.8-1.5% eurycomanone)

Benefits

Total testosterone increase meta-analysis (Leisegang 2022, PMID 36013514)

Leisegang K et al. 2022 (PMID 36013514, PMC9415500, Medicina 58(8):1047) — systematic review and meta-analysis per PRISMA guidelines. 9 studies in review, 5 RCTs in meta-analysis. Significant increase in total testosterone (SMD 1.352, 95% CI 0.565-2.138, p=0.001). Effect confirmed in the hypogonadism subgroup. The most rigorous meta-analytic evidence base for any testosterone-supporting herbal supplement to date.

Supported by Trial 1

Erectile function and testosterone in ADAM (Henkel 2021)

Henkel R et al. 2021 (PMID 33541567, Maturitas) — 6-month 4-arm RCT in ADAM (Androgen Deficiency of Aging Males) men. E. longifolia plus concurrent training improved erectile function and testosterone in ~50% of participants. Real-world clinical population evidence — combination with exercise reflects how the supplement is typically used in practice.

Supported by Trial 2

Hypogonadism + LOH testosterone (Tambi 2012)

Tambi MI 2012 — 76 patients with hypogonadism plus late-onset hypogonadism (LOH) on Physta®. Significant testosterone increase observed. Provides the foundational hypogonadism subgroup evidence reflected in the Leisegang 2022 meta-analysis.

Supported by Trial 3, Trial 1

Healthy older volunteers testosterone (50-70 years RCT)

Smaller RCT in healthy older volunteers aged 50-70 years confirmed testosterone increase. Age-related testosterone decline indication evidence.

Supported by Trial 1, Trial 3

Sedentary young males testosterone (Hamzah 2003)

Hamzah S 2003 — sedentary young males showed testosterone increase with E. longifolia supplementation. Earlier evidence in younger population — different age group than the hypogonadism and ADAM trials.

Supported by Trial 2, Trial 1

Stress and cortisol reduction (Talbott 2013)

Talbott SM et al. 2013 — cortisol/testosterone ratio improvement in moderately stressed subjects. Broader application beyond pure testosterone-boosting — relevant for stressed populations where elevated cortisol suppresses testosterone.

Supported by Trial 1, Trial 2

Estrogen modulation (anti-estrogenic in men)

Eurycomanone inhibits aromatase — the enzyme converting testosterone to estradiol. Anti-estrogenic mechanism in men is biochemically distinct from direct testosterone biosynthesis: the same circulating testosterone is preserved as testosterone rather than being converted to estradiol. Mechanism complement to direct testosterone support.

Supported by Trial 2, Trial 1

Mechanism of action

1

Aromatase inhibition (anti-estrogenic mechanism in men)

Eurycomanone inhibits aromatase — preventing conversion of testosterone to estradiol. Distinct from direct testosterone biosynthesis support: preserves circulating testosterone as testosterone rather than allowing estradiol conversion. Mechanistically aligns with prescription aromatase inhibitors (anastrozole, letrozole) but at a much milder magnitude.

2

Testosterone biosynthesis support (Leydig cells)

Eurycomanone supports testosterone biosynthesis in Leydig cells — the primary testosterone-producing cell in the testis. Mechanism complement to the aromatase inhibition; together they raise both production and protect from conversion.

3

Cortisol / HPA axis modulation

Talbott 2013 mechanism — modulates HPA axis cortisol response. In moderately stressed populations, the cortisol/testosterone ratio improves through both reduced cortisol and supported testosterone.

4

Quassinoid bioactivity (distinct chemical class)

Quassinoids are a distinct chemical class with multiple biological activities. Eurycomanone is the primary bioactive among Tongkat Ali quassinoids; β-anhydroxonoeurycomalactone, eurycolactone, and other quassinoids contribute additional bioactivity.

5

9-hydroxycanthin-6-one alkaloid bioactivity

9-hydroxycanthin-6-one is an alkaloid in E. longifolia with additional bioactivity. Contributes to the multi-compound mechanism profile.

6

SHBG modulation

Sex hormone binding globulin (SHBG) modulation affects free (bioavailable) testosterone. Lower SHBG means more free testosterone available for tissue effects despite similar total testosterone — a mechanism contributing to the clinical efficacy beyond what total testosterone changes alone would predict.

Clinical trials

1
Leisegang 2022 — Eurycoma longifolia Testosterone Meta-Analysis (PMID 36013514, PIVOTAL)

Leisegang K et al. 2022 (PMID 36013514, PMC9415500, Medicina 58(8):1047). Systematic review and meta-analysis per PRISMA guidelines. 9 studies in review, 5 RCTs in meta-analysis. Significant increase in total testosterone (SMD 1.352, 95% CI 0.565-2.138, p=0.001). Effect confirmed in hypogonadism subgroup. The most rigorous meta-analytic evidence for any testosterone-supporting herbal supplement.

2
Henkel 2021 — ADAM 6-Month RCT (PMID 33541567)

Henkel R et al. 2021 (Maturitas). 6-month 4-arm RCT in ADAM (Androgen Deficiency of Aging Males) men. E. longifolia + concurrent training improved erectile function and testosterone in ~50% of participants. Real-world clinical population evidence with exercise combination.

3
Tambi 2012 — Physta® Hypogonadism + LOH Trial

Tambi MI 2012. 76 patients with hypogonadism plus late-onset hypogonadism (LOH) on Physta®. Significant testosterone increase observed. Foundational hypogonadism subgroup evidence.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated at typical doses.
Mild GI upset, restlessness, insomnia (rare).
Theoretical androgen-related effects: irritability, aggression at high doses.
Pregnancy/lactation: AVOID (theoretical hormonal effects).
Hormone-sensitive cancers (prostate cancer history): CAUTION — consult oncologist.
Long-term safety: extensive Malaysian traditional use + clinical trials supportive at typical doses.
Heavy metal contamination concern with non-standardized extracts (24/41 Malaysian products in older surveys had contamination) — choose certified branded extracts (Physta®, LJ100®).

Important Drug interactions

Testosterone replacement therapy: theoretical synergistic effects — consult endocrinologist.
Anabolic steroids: theoretical synergistic — caution.
Anticoagulants: theoretical mild antiplatelet effects.
Diabetes medications: monitor blood glucose.
Hypertensives: theoretical mild effects.
Most medications: well-tolerated combination profile at typical doses.
Aromatase inhibitors (for breast cancer treatment): theoretical synergistic effects — consult oncologist.

More Testosterone Ingredients

Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…
Men's Health
Testofen® (Fenugreek for Male Vitality)
Testofen® is a STANDARDIZED FENUGREEK SEED EXTRACT developed by Saanroo (formerly Gencor P…
Athletic Performance
RipFACTOR® (Botanical Muscle Accelerator)
RipFACTOR® (PLT Health Solutions / Laila Nutraceuticals) is a multi-patented botanical mus…
Sleep Health
Shoden® (35% Withanolide Glycoside Ashwagandha)
Shoden® (Arjuna Natural) is the world's highest-potency standardized ashwagandha extract —…

Explore Other Ingredients

Athletic Performance
Maca
Maca (Lepidium meyenii), a Peruvian root vegetable from the Andes, is traditionally used t…
Athletic Performance
Oxystorm® (Red Spinach Nitrate)
Oxystorm® (PLT Health Solutions) is a standardized red spinach (Amaranthus dubius) extract…
Cognitive
Phosphatidylserine
Phosphatidylserine, a phospholipid found in cell membranes, supports cognitive function an…

Frequently asked questions about Eurycomanone (Tongkat Ali Quassinoid)

What is the recommended dosage of Eurycomanone (Tongkat Ali Quassinoid)?

The clinically studied dose for Eurycomanone (Tongkat Ali Quassinoid) is STANDARDIZED EXTRACTS: Physta® 200-400 mg/day (Tambi 2012 hypogonadism). LJ100®: 100-200 mg/day. PURIFIED EURYCOMANONE: 50-200 mg/day. Standard total range: 200-400 mg/day. Avoid in pregnancy and hormone-sensitive cancers. Standardized branded extracts preferable due to historical heavy metal contamination concerns with non-standardized Malaysian products.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Eurycomanone (Tongkat Ali Quassinoid) used for?

Eurycomanone (Tongkat Ali Quassinoid) is studied for total testosterone increase meta-analysis (leisegang 2022, pmid 36013514), erectile function and testosterone in adam (henkel 2021), hypogonadism + loh testosterone (tambi 2012). Leisegang K et al. 2022 (PMID 36013514, PMC9415500, Medicina 58(8):1047) — systematic review and meta-analysis per PRISMA guidelines. 9 studies in review, 5 RCTs in meta-analysis. Significant increase in total testosterone (SMD 1.352, 95% CI 0.565-2.

Are there side effects from taking Eurycomanone (Tongkat Ali Quassinoid)?

Reported potential side effects may include: Generally well-tolerated at typical doses. Mild GI upset, restlessness, insomnia (rare). Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Eurycomanone (Tongkat Ali Quassinoid) interact with medications?

Known drug interactions may include: Testosterone replacement therapy: theoretical synergistic effects — consult endocrinologist. Anabolic steroids: theoretical synergistic — caution. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Eurycomanone (Tongkat Ali Quassinoid) good for testosterone?

Yes, Eurycomanone (Tongkat Ali Quassinoid) is researched for Testosterone support. Leisegang K et al. 2022 (PMID 36013514, PMC9415500, Medicina 58(8):1047) — systematic review and meta-analysis per PRISMA guidelines. 9 studies in review, 5 RCTs in meta-analysis. Significant increase in total testosterone (SMD 1.352, 95% CI 0.565-2.138, p=0.001).